{
    "ticker": "GRTX",
    "name": "Galera Therapeutics, Inc.",
    "description": "Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to improve the treatment of cancer. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera is committed to advancing its proprietary drug platform that targets the tumor microenvironment to enhance the effectiveness of standard cancer therapies. The company\u2019s lead product candidate, GC4419, is designed to mitigate the debilitating side effects of radiation therapy, particularly in patients with head and neck cancers. By selectively targeting the harmful oxidative stress generated by radiation, GC4419 aims to improve patient quality of life and treatment outcomes. Galera is also exploring additional indications and combinations with other cancer treatments to expand the therapeutic potential of its drug candidates. With a dedicated team of scientists and clinicians, Galera is at the forefront of transforming cancer care and providing hope for patients facing difficult treatment regimens. The company\u2019s research is grounded in robust scientific principles and a commitment to addressing unmet medical needs in oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Malvern, Pennsylvania, USA",
    "founded": "2012",
    "website": "https://www.galeratx.com",
    "ceo": "Melanie A. McCullough",
    "social_media": {
        "twitter": "https://twitter.com/Galera_Therapies",
        "linkedin": "https://www.linkedin.com/company/galera-therapeutics/"
    },
    "investor_relations": "https://investors.galeratx.com",
    "key_executives": [
        {
            "name": "Melanie A. McCullough",
            "position": "CEO"
        },
        {
            "name": "Jesse S. Goodman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Products",
            "products": [
                "GC4419"
            ]
        }
    ],
    "seo": {
        "meta_title": "Galera Therapeutics, Inc. | Innovative Cancer Therapies",
        "meta_description": "Galera Therapeutics, Inc. is dedicated to developing innovative therapies for cancer treatment, focusing on enhancing the effectiveness of radiation therapy and improving patient outcomes.",
        "keywords": [
            "Galera Therapeutics",
            "Cancer Treatment",
            "GC4419",
            "Oncology",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Galera Therapeutics known for?",
            "answer": "Galera Therapeutics is known for its development of innovative cancer therapies, particularly its lead product candidate GC4419."
        },
        {
            "question": "Who is the CEO of Galera Therapeutics?",
            "answer": "Melanie A. McCullough is the CEO of Galera Therapeutics, Inc."
        },
        {
            "question": "Where is Galera Therapeutics headquartered?",
            "answer": "Galera Therapeutics is headquartered in Malvern, Pennsylvania, USA."
        },
        {
            "question": "What is GC4419?",
            "answer": "GC4419 is a drug candidate developed by Galera Therapeutics designed to improve the effectiveness of radiation therapy for cancer patients."
        },
        {
            "question": "When was Galera Therapeutics founded?",
            "answer": "Galera Therapeutics was founded in 2012."
        }
    ],
    "competitors": [
        "NVS",
        "BMY",
        "AMGN",
        "VRTX"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "AVEO"
    ]
}